Rapamycin for Longevity: What the PEARL Trial Actually Found After 48 Weeks in Humans
114 adults, 48 weeks, placebo-controlled: the first rigorous human rapamycin longevity trial found a 5% lean mass gain in women and a favorable safety profile.
114 adults, 48 weeks, placebo-controlled: the first rigorous human rapamycin longevity trial found a 5% lean mass gain in women and a favorable safety profile.